[Form 4] ABBVIE INC. Insider Trading Activity
Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.
Azita Saleki-Gerhardt, Executive Vice President e Chief Operations Officer di AbbVie Inc. (ABBV), ha dichiarato operazioni effettuate il 12/08/2025 in cui ha esercitato opzioni su azioni riservate ai dipendenti e contestualmente ha venduto le azioni risultanti. Ha acquisito 42.370 azioni mediante esercizio a un prezzo di esercizio riportato di $54.86 per azione e ha venduto lo stesso giorno 42.370 azioni a un prezzo medio ponderato di vendita di $198.42 per azione. Dopo queste operazioni, la sua propriet脿 diretta beneficiaria riportata 猫 diminuita da 219.662 azioni a 177.292 azioni. Il Modulo 4 indica che 2.647 azioni sono detenute in un programma di risparmio AbbVie e 3.873 azioni sono intestate al coniuge (per le quali ella dichiara di non avere benefici). Le operazioni sono state segnalate da un procuratore e il deposito contiene una nota esplicativa che i prezzi di vendita riportati rappresentano un intervallo compreso tra $198.34 e $198.58.
Azita Saleki-Gerhardt, Vicepresidenta Ejecutiva y Chief Operations Officer de AbbVie Inc. (ABBV), inform贸 transacciones el 12/08/2025 en las que 别箩别谤肠颈贸 opciones sobre acciones para empleados y, al mismo tiempo, vendi贸 las acciones resultantes. Adquiri贸 42.370 acciones mediante el ejercicio a un precio de ejercicio declarado de $54.86 por acci贸n y vendi贸 ese mismo d铆a 42.370 acciones a un precio medio ponderado de venta de $198.42 por acci贸n. Despu茅s de estas operaciones, su propiedad beneficiaria directa reportada disminuy贸 de 219.662 acciones a 177.292 acciones. El Formulario 4 se帽ala que 2.647 acciones est谩n en un programa de ahorro de AbbVie y 3.873 acciones est谩n a nombre de su c贸nyuge (sobre las cuales ella renuncia a la propiedad beneficiaria). Las transacciones fueron informadas por un apoderado y la presentaci贸n incluye una nota explicativa que indica que los precios de venta reportados representan un rango entre $198.34 y $198.58.
Azita Saleki-Gerhardt, AbbVie Inc. (ABBV)鞚� 攵�靷灔 瓴� 斓滉碃鞖挫榿毂呾瀯鞛�(Executive Vice President and Chief Operations Officer)電� 2025-08-12鞛愲 歆侅洂 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃 霃欖嫓鞐� 氚滌儩頃� 欤检嫕鞚� 毵る弰頃� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽厐電� 頄夓偓搿� 42,370欤茧ゼ 旆摑頄堨溂氅�, 鞁犼碃霅� 頄夓偓臧�瓴╈潃 欤茧嫻 $54.86鞓�瓿� 臧欖潃 雮� 42,370欤茧ゼ 臧�欷戫弶攴� 毵る弰臧� $198.42搿� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃霅� 歆侅爲鞝� 鞁れ 靻岇湢 欤检嫕 靾橂姅 219,662欤检棎靹� 177,292欤茧 臧愳唽頄堨姷雼堧嫟. Form 4鞐愲姅 2,647欤缄皜 AbbVie 鞝�於� 頂勲攴鸽灗鞐� 氤搓磤霅橃柎 鞛堦碃 3,873欤茧姅 氚办毎鞛� 氇呾潣搿� 霅橃柎 鞛堨柎(攴胳棎 雽�頃� 鞁れ 靻岇湢甓岇潉 攵�鞚疙暔)霛缄碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓯半灅電� 雽�毽澑(氤�順胳偓 雽�毽澑)鞐� 鞚橅暣 氤搓碃霅橃棃瓿� 鞝滌稖 靹滊鞐愲姅 氤搓碃霅� 毵る弰 臧�瓴╈澊 $198.34鞐愳劀 $198.58 靷澊鞚� 氩旍渼毳� 雮橅儉雮鸽嫟電� 靹る獏 臧侅＜臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Azita Saleki-Gerhardt, Executive Vice President et Chief Operations Officer d'AbbVie Inc. (ABBV), a d茅clar茅 des op茅rations en date du 12/08/2025 indiquant qu'elle a 别虫别谤肠茅 des options d'achat d'actions r茅serv茅es aux employ茅s et a simultan茅ment vendu les actions obtenues. Elle a acquis 42 370 actions par exercice 脿 un prix d'exercice d茅clar茅 de $54.86 par action et a vendu le m锚me jour 42 370 actions 脿 un prix de vente moyen pond茅r茅 de $198.42 par action. 脌 la suite de ces op茅rations, sa propri茅t茅 b茅n茅ficiaire directe d茅clar茅e est pass茅e de 219 662 actions 脿 177 292 actions. Le formulaire 4 pr茅cise que 2 647 actions sont d茅tenues dans un plan d'茅pargne AbbVie et que 3 873 actions sont au nom de son conjoint (dont elle d茅cline la propri茅t茅 b茅n茅ficiaire). Les transactions ont 茅t茅 signal茅es par un mandataire et le d茅p么t comprend une note explicative indiquant que les prix de vente d茅clar茅s repr茅sentent une fourchette comprise entre $198.34 et $198.58.
Azita Saleki-Gerhardt, Executive Vice President und Chief Operations Officer von AbbVie Inc. (ABBV), meldete Transaktionen vom 12.08.2025, wonach sie Mitarbeiteraktienoptionen 补耻蝉眉产迟别 und die daraus resultierenden Aktien gleichzeitig verkaufte. Sie erwarb durch Aus眉bung 42.370 Aktien zu einem gemeldeten Aus眉bungspreis von $54.86 je Aktie und verkaufte am selben Tag 42.370 Aktien zu einem gewichteten durchschnittlichen Verkaufspreis von $198.42 je Aktie. Nach diesen Transaktionen verringerte sich ihr gemeldeter direkter wirtschaftlicher Besitz von 219.662 Aktien auf 177.292 Aktien. Im Formular 4 wird angegeben, dass 2.647 Aktien in einem AbbVie-Sparprogramm gehalten werden und 3.873 Aktien dem Ehepartner geh枚ren (f眉r die sie das wirtschaftliche Eigentum bestreitet). Die Transaktionen wurden von einem Bevollm盲chtigten gemeldet; die Einreichung enth盲lt eine erl盲uternde Fu脽note, dass die gemeldeten Verkaufspreise eine Spanne zwischen $198.34 und $198.58 darstellen.
- None.
- Insider sale of 42,370 shares reported on 08/12/2025, reducing direct beneficial ownership from 219,662 to 177,292 shares
- Shares sold at weighted-average $198.42 (range $198.34鈥�$198.58) on the same day as option exercise, indicating insider liquidity
Insights
TL;DR: Insider exercised options at $54.86 and sold the shares same day at ~ $198.42, reducing direct holdings by 42,370 shares.
This Form 4 documents a routine option exercise and concurrent sale by a senior officer. The exercise converted outstanding employee stock options into 42,370 common shares at the stated exercise price of $54.86 per share, and those shares were sold on the same date at a weighted-average price of $198.42. Post-transaction direct beneficial ownership is reported as 177,292 shares. The filing also discloses small indirect holdings in a savings program (2,647 shares) and shares held by the reporting person鈥檚 spouse (3,873), which the reporting person disclaims. For investors, the filing is a clear, contemporaneous disclosure of insider liquidity but does not provide additional company-operating information.
TL;DR: Transaction is a standard exercise-and-sale by a named officer; disclosure appears complete with explanatory footnotes.
The filing identifies the reporting person as ABBV鈥檚 EVP and Chief Operations Officer and includes required explanations: the exercise was pursuant to the AbbVie 2013 Incentive Stock Program and became exercisable in prior annual increments. The Form 4 includes a footnote disclosing the weighted-average sale price range and offers to provide detailed per-price sale information upon request. The signature is by an attorney-in-fact. From a governance and compliance perspective, the disclosure is appropriately detailed and follows Section 16 reporting norms.
Azita Saleki-Gerhardt, Executive Vice President e Chief Operations Officer di AbbVie Inc. (ABBV), ha dichiarato operazioni effettuate il 12/08/2025 in cui ha esercitato opzioni su azioni riservate ai dipendenti e contestualmente ha venduto le azioni risultanti. Ha acquisito 42.370 azioni mediante esercizio a un prezzo di esercizio riportato di $54.86 per azione e ha venduto lo stesso giorno 42.370 azioni a un prezzo medio ponderato di vendita di $198.42 per azione. Dopo queste operazioni, la sua propriet脿 diretta beneficiaria riportata 猫 diminuita da 219.662 azioni a 177.292 azioni. Il Modulo 4 indica che 2.647 azioni sono detenute in un programma di risparmio AbbVie e 3.873 azioni sono intestate al coniuge (per le quali ella dichiara di non avere benefici). Le operazioni sono state segnalate da un procuratore e il deposito contiene una nota esplicativa che i prezzi di vendita riportati rappresentano un intervallo compreso tra $198.34 e $198.58.
Azita Saleki-Gerhardt, Vicepresidenta Ejecutiva y Chief Operations Officer de AbbVie Inc. (ABBV), inform贸 transacciones el 12/08/2025 en las que 别箩别谤肠颈贸 opciones sobre acciones para empleados y, al mismo tiempo, vendi贸 las acciones resultantes. Adquiri贸 42.370 acciones mediante el ejercicio a un precio de ejercicio declarado de $54.86 por acci贸n y vendi贸 ese mismo d铆a 42.370 acciones a un precio medio ponderado de venta de $198.42 por acci贸n. Despu茅s de estas operaciones, su propiedad beneficiaria directa reportada disminuy贸 de 219.662 acciones a 177.292 acciones. El Formulario 4 se帽ala que 2.647 acciones est谩n en un programa de ahorro de AbbVie y 3.873 acciones est谩n a nombre de su c贸nyuge (sobre las cuales ella renuncia a la propiedad beneficiaria). Las transacciones fueron informadas por un apoderado y la presentaci贸n incluye una nota explicativa que indica que los precios de venta reportados representan un rango entre $198.34 y $198.58.
Azita Saleki-Gerhardt, AbbVie Inc. (ABBV)鞚� 攵�靷灔 瓴� 斓滉碃鞖挫榿毂呾瀯鞛�(Executive Vice President and Chief Operations Officer)電� 2025-08-12鞛愲 歆侅洂 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃 霃欖嫓鞐� 氚滌儩頃� 欤检嫕鞚� 毵る弰頃� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽厐電� 頄夓偓搿� 42,370欤茧ゼ 旆摑頄堨溂氅�, 鞁犼碃霅� 頄夓偓臧�瓴╈潃 欤茧嫻 $54.86鞓�瓿� 臧欖潃 雮� 42,370欤茧ゼ 臧�欷戫弶攴� 毵る弰臧� $198.42搿� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃霅� 歆侅爲鞝� 鞁れ 靻岇湢 欤检嫕 靾橂姅 219,662欤检棎靹� 177,292欤茧 臧愳唽頄堨姷雼堧嫟. Form 4鞐愲姅 2,647欤缄皜 AbbVie 鞝�於� 頂勲攴鸽灗鞐� 氤搓磤霅橃柎 鞛堦碃 3,873欤茧姅 氚办毎鞛� 氇呾潣搿� 霅橃柎 鞛堨柎(攴胳棎 雽�頃� 鞁れ 靻岇湢甓岇潉 攵�鞚疙暔)霛缄碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓯半灅電� 雽�毽澑(氤�順胳偓 雽�毽澑)鞐� 鞚橅暣 氤搓碃霅橃棃瓿� 鞝滌稖 靹滊鞐愲姅 氤搓碃霅� 毵る弰 臧�瓴╈澊 $198.34鞐愳劀 $198.58 靷澊鞚� 氩旍渼毳� 雮橅儉雮鸽嫟電� 靹る獏 臧侅＜臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Azita Saleki-Gerhardt, Executive Vice President et Chief Operations Officer d'AbbVie Inc. (ABBV), a d茅clar茅 des op茅rations en date du 12/08/2025 indiquant qu'elle a 别虫别谤肠茅 des options d'achat d'actions r茅serv茅es aux employ茅s et a simultan茅ment vendu les actions obtenues. Elle a acquis 42 370 actions par exercice 脿 un prix d'exercice d茅clar茅 de $54.86 par action et a vendu le m锚me jour 42 370 actions 脿 un prix de vente moyen pond茅r茅 de $198.42 par action. 脌 la suite de ces op茅rations, sa propri茅t茅 b茅n茅ficiaire directe d茅clar茅e est pass茅e de 219 662 actions 脿 177 292 actions. Le formulaire 4 pr茅cise que 2 647 actions sont d茅tenues dans un plan d'茅pargne AbbVie et que 3 873 actions sont au nom de son conjoint (dont elle d茅cline la propri茅t茅 b茅n茅ficiaire). Les transactions ont 茅t茅 signal茅es par un mandataire et le d茅p么t comprend une note explicative indiquant que les prix de vente d茅clar茅s repr茅sentent une fourchette comprise entre $198.34 et $198.58.
Azita Saleki-Gerhardt, Executive Vice President und Chief Operations Officer von AbbVie Inc. (ABBV), meldete Transaktionen vom 12.08.2025, wonach sie Mitarbeiteraktienoptionen 补耻蝉眉产迟别 und die daraus resultierenden Aktien gleichzeitig verkaufte. Sie erwarb durch Aus眉bung 42.370 Aktien zu einem gemeldeten Aus眉bungspreis von $54.86 je Aktie und verkaufte am selben Tag 42.370 Aktien zu einem gewichteten durchschnittlichen Verkaufspreis von $198.42 je Aktie. Nach diesen Transaktionen verringerte sich ihr gemeldeter direkter wirtschaftlicher Besitz von 219.662 Aktien auf 177.292 Aktien. Im Formular 4 wird angegeben, dass 2.647 Aktien in einem AbbVie-Sparprogramm gehalten werden und 3.873 Aktien dem Ehepartner geh枚ren (f眉r die sie das wirtschaftliche Eigentum bestreitet). Die Transaktionen wurden von einem Bevollm盲chtigten gemeldet; die Einreichung enth盲lt eine erl盲uternde Fu脽note, dass die gemeldeten Verkaufspreise eine Spanne zwischen $198.34 und $198.58 darstellen.
FAQ
What transactions did ABBV insider Azita Saleki-Gerhardt report on 08/12/2025?
How did the Form 4 affect Azita Saleki-Gerhardt's ownership in ABBV?
Are there any indirect holdings disclosed for Azita Saleki-Gerhardt in this filing?
What option plan governed the exercised options?
Who signed the Form 4 filing?
